Research programme: EP4 receptor agonists - PfizerAlternative Names: CP-432; EP4 receptor agonists - Pfizer
Latest Information Update: 05 Aug 2009
At a glance
- Originator Pfizer
- Mechanism of Action Prostaglandin E4 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 05 Aug 2009 Discontinued - Preclinical for Osteoporosis in USA (SC)
- 04 Jul 2006 Preclinical trials in Osteoporosis in USA (SC)